Literature DB >> 1934923

Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease.

R de Noronha1, B A Taylor, G Wild, D R Triger, M Greaves.   

Abstract

Thrombocytopenia is a common finding in subjects with chronic liver diseases. A variety of mechanisms may underlie this. Immunological disturbances are commonly a feature in chronic liver disease, including hyperglobulinaemia and the presence of autoantibodies and circulating immune complexes and immune mechanisms could therefore contribute to thrombocytopenia. We have investigated the relationships between blood platelet count, serum IgG and IgG immune complexes and IgG associated with platelets in 92 subjects with chronic liver disease (27 with chronic active hepatitis, 38 with primary biliary cirrhosis and 27 with alcoholic liver disease). Severity of liver impairment was a major determinant of degree of thrombocytopenia. Also, an inverse relationship was demonstrated between platelet count and platelet-associated IgG. In subjects with chronic active hepatitis the relationships between platelet count, serum IgG immune complexes and platelet-associated IgG were consistent with a role for immune mechanisms in general and immune complexes in particular as mediators of the thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934923     DOI: 10.1111/j.1365-2257.1991.tb00261.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  10 in total

1.  Severe thrombocytopenia secondary to asymptomatic cytomegalovirus infection in an immunocompetent host.

Authors:  J G Wright
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

2.  Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C.

Authors:  Mohamed A Metwally; Claudia O Zein; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

3.  The Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis.

Authors:  Omar I Massoud; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

4.  Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.

Authors:  Z Karasu; A Gurakar; B Kerwin; S Hulagu; A Jazzar; R McFadden; B Nour; A Sebastian; F Cassidy; K Stokes; D H Van Thiel; H Wright
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

5.  Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C.

Authors:  Tetsuro Sekiguchi; Takeaki Nagamine; Hitoshi Takagi; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

Review 6.  Management of thrombocytopenia in advanced liver disease.

Authors:  V G R Gangireddy; P C Kanneganti; S Sridhar; S Talla; T Coleman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09-15

7.  Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis.

Authors:  S P Lawrence; D C Lezotte; J D Durham; D A Kumpe; G T Everson; B M Bilir
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

8.  Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C.

Authors:  Zeki Karasu; Fatih Tekin; Galip Ersoz; Fulya Gunsar; Yucel Batur; Tankut Ilter; Ulus S Akarca
Journal:  Dig Dis Sci       Date:  2007-04-27       Impact factor: 3.487

9.  Platelet IgG antibodies are significantly increased in chronic liver disease.

Authors:  Dimitrios Christodoulou; Konstantinos Katsanos; Eleftheria Zervou; Vasileios Theopistos; Athanasios Papathanasopoulos; Leonidas Christou; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2011

10.  Efficacy and safety of laparoscopic splenectomy for hypersplenism secondary to portal hypertension after transjugular intrahepatic portosystemic shunt.

Authors:  Yingying Li; Zuojin Liu; Chang'an Liu
Journal:  BMC Gastroenterol       Date:  2021-02-11       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.